Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Riwel-IS
Riwel-IS is a clinically proven anti-tuberculosis therapy containing Rifampicin and Isoniazid, designed to effectively eliminate Mycobacterium tuberculosis. It is a cornerstone of first-line TB treatment, ensuring rapid bacterial clearance and resistance prevention.
Uses of Riwel-IS
Riwel-IS is indicated for the treatment and prevention of:
Active Pulmonary & Extrapulmonary Tuberculosis
Latent Tuberculosis Infection (LTBI) Prophylaxis
Multi-Drug Regimen for Drug-Susceptible TB
Prevention of TB Transmission in High-Risk Patients
Benefits of Riwel-IS
Dual Mechanism for Potent Anti-TB Action
Prevents Disease Progression & Drug Resistance
Highly Effective Against Active & Latent TB
Reduces Transmission & Relapse Risk
Essential Component of Standard TB Therapy
Mechanism of Action of Riwel-IS
Rifampicin inhibits bacterial RNA polymerase, preventing RNA transcription and protein synthesis, leading to bacterial death.
Isoniazid disrupts mycolic acid synthesis, weakening the bacterial cell wall and enhancing bactericidal activity.
The combination ensures complete bacterial eradication, minimizing treatment failure and drug resistance.